SCHEMBL4450385

SCHEMBL4450385

COC(=O)c1cc(Cl)ccc1Oc1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 2/20 0.56
TDP1 Q9NUW8 1/20 0.52
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
SLC6A4 P31645 2/20 0.49
MRGPRX4 Q96LA9 1/20 0.49
HTR2A P28223 1/20 0.49
KCNH2 Q12809 1/20 0.49
ABL1 P00519 1/20 0.49
EPAS1 Q99814 1/20 0.48
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
PTGER2 P43116 1/20 0.47
SLC6A3 Q01959 1/20 0.47
LMNA P02545 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4449372 0.92 KDM4E (0.59) PTGER4TDP1CYP1A2CYP3A4CYP2C19
SCHEMBL30974620 0.90 L3MBTL1 (0.58) PTGER4TDP1CYP1A2CYP3A4CYP2C19
SCHEMBL5362837 0.90 L3MBTL1 (0.58) PTGER4TDP1CYP1A2CYP3A4CYP2C19
SCHEMBL4446808 0.89 PTGER4 (0.59) PTGER4TDP1SLC6A4MRGPRX4ABL1
SCHEMBL29250442 0.88 ALDH1A1 (0.53) PTGER4TDP1CYP1A2CYP3A4CYP2C19
SCHEMBL29250438 0.88 PTGER4 (0.48) PTGER4TDP1SLC6A4MRGPRX4ABL1
SCHEMBL30974583 0.88 PTGER4 (0.48) PTGER4TDP1SLC6A4MRGPRX4ABL1
SCHEMBL4445314 0.83 MRGPRX4 (0.60) PTGER4CYP1A2CYP3A4CYP2C19SLC6A4
SCHEMBL5357436 0.83 TDP1 (0.53) PTGER4TDP1SLC6A4HTR2AKCNH2
SCHEMBL8274395 0.82 PTGER4 (0.52) PTGER4CYP1A2CYP3A4CYP2C19SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663979-B1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2013-10-09 EP disclosed
CN-1867551-B Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists RAQUALIA PHARMA INC 2013-09-11 CN disclosed
WO-2005102389-A9 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2009-04-30 WO disclosed
WO-2005102389-A9 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PROD INC (US) 2009-04-30 WO disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
EP-1740211-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-01-10 EP disclosed
CN-1867551-A Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists PFIZER (US) 2006-11-22 CN disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 EP disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 WO disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 PTGER4 13/4885TDP1 4559/4885CYP1A2 102/4885
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PTGER4, PTGER2, OPRL1 PTGER4 1/4885TDP1 4624/4885CYP1A2 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.